This video examines the targeting of IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia.
In this video, Courtney D. DiNardo, MD, of MD Anderson Cancer Center in Houston, discusses targeting IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia (AML).
IDH mutations occur in roughly 20% of AML patients and recent novel therapies have proven to be effective in this setting. A phase I trial on the novel IDH2-inhibitor enasidenib in relapsed/refractory AML was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
DiNardo, who has been involved in many of the AML studies using IDH inhibitors, gave a presentation on this topic during an education session at the meeting.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment
July 6th 2020The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.